- Home
- LFST vs EVO Comparison
LFST vs EVO Comparison
Compare LFST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- EVO
- Stock Information
- Founded
- LFST 2015
- EVO 1993
- Country
- LFST United States
- EVO Germany
- Employees
- LFST N/A
- EVO N/A
- Industry
- LFST Medical/Nursing Services
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- LFST Health Care
- EVO Health Care
- Exchange
- LFST Nasdaq
- EVO Nasdaq
- Market Cap
- LFST 1.9B
- EVO 1.5B
- IPO Year
- LFST 2021
- EVO 2021
- Fundamental
- Price
- LFST $4.51
- EVO $4.07
- Analyst Decision
- LFST Strong Buy
- EVO Buy
- Analyst Count
- LFST 5
- EVO 2
- Target Price
- LFST $8.50
- EVO $5.90
- AVG Volume (30 Days)
- LFST 2.4M
- EVO 112.1K
- Earning Date
- LFST 08-07-2025
- EVO 08-13-2025
- Dividend Yield
- LFST N/A
- EVO N/A
- EPS Growth
- LFST N/A
- EVO N/A
- EPS
- LFST N/A
- EVO N/A
- Revenue
- LFST $1,283,503,000.00
- EVO $851,944,444.00
- Revenue This Year
- LFST $15.27
- EVO $10.08
- Revenue Next Year
- LFST $13.94
- EVO $10.99
- P/E Ratio
- LFST N/A
- EVO N/A
- Revenue Growth
- LFST 16.31
- EVO 1.50
- 52 Week Low
- LFST $4.48
- EVO $2.84
- 52 Week High
- LFST $8.61
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- LFST 27.78
- EVO 47.66
- Support Level
- LFST $4.61
- EVO $4.12
- Resistance Level
- LFST $4.88
- EVO $4.26
- Average True Range (ATR)
- LFST 0.20
- EVO 0.11
- MACD
- LFST -0.01
- EVO -0.01
- Stochastic Oscillator
- LFST 4.46
- EVO 54.84
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.